Cynthia S Bonhof1,2, Lonneke V van de Poll-Franse3,4,5, Dareczka K Wasowicz6, Laurens V Beerepoot7, Gerard Vreugdenhil8, Floortje Mols3,4. 1. Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic disorders, Tilburg University, Tilburg, The Netherlands. C.S.Bonhof@tilburguniversity.edu. 2. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. C.S.Bonhof@tilburguniversity.edu. 3. Department of Medical and Clinical Psychology, CoRPS - Center of Research on Psychology in Somatic disorders, Tilburg University, Tilburg, The Netherlands. 4. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands. 5. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 6. Department of Surgery, Elisabeth-TweeSteden hospital, Tilburg, the Netherlands. 7. Department of Internal Medicine, Elisabeth-TweeSteden hospital, Tilburg, the Netherlands. 8. Department of Internal Medicine, Máxima Medical Centre, Eindhoven and Veldhoven, The Netherlands.
Abstract
PURPOSE: To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis. METHODS: All newly diagnosed CRC patients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis. RESULTS: Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level. CONCLUSIONS: Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient's lives. IMPLICATIONS FOR CANCER SURVIVORS: Patients need to be informed of both CIPN and the impact on HRQoL.
PURPOSE: To gain more insight into the course of chemotherapy-induced peripheral neuropathy (CIPN) and its impact on health-related quality of life (HRQoL) in a population-based sample of colorectal cancer (CRC) patients up to 2 years after diagnosis. METHODS: All newly diagnosed CRCpatients from four hospitals in the Netherlands were eligible for participation in an ongoing prospective cohort study. Patients (n = 340) completed questions on CIPN (EORTC QLQ-CIPN20) and HRQoL (EORTC QLQ-C30) before initial treatment (baseline) and 1 and 2 years after diagnosis. RESULTS: Among chemotherapy-treated patients (n = 105), a high sensory peripheral neuropathy (SPN) level was reported by 57% of patients at 1 year, and 47% at 2-year follow-up, whereas a high motor peripheral neuropathy (MPN) level was reported by 47% and 28%, at years 1 and 2, respectively. Linear mixed model analyses showed that SPN and MPN symptoms significantly increased from baseline to 1-year follow-up and did not return to baseline level after 2 years. Patients with a high SPN or MPN level reported a worse global quality of life and a worse physical, role, emotional, cognitive, and social functioning compared with those with a low SPN or MPN level. CONCLUSIONS: Future studies should focus on understanding the mechanisms underlying CIPN so targeted interventions can be developed to reduce the impact of CIPN on patient's lives. IMPLICATIONS FOR CANCER SURVIVORS: Patients need to be informed of both CIPN and the impact on HRQoL.
Entities:
Keywords:
Colorectal cancer; Health-related quality of life; PROFILES; Peripheral neuropathy
Authors: Kim Cocks; Madeleine T King; Galina Velikova; Marrissa Martyn St-James; Peter M Fayers; Julia M Brown Journal: J Clin Oncol Date: 2010-11-22 Impact factor: 44.544
Authors: Susanna B Park; Paola Alberti; Noah A Kolb; Jennifer S Gewandter; Angelo Schenone; Andreas A Argyriou Journal: J Peripher Nerv Syst Date: 2019-10 Impact factor: 3.494
Authors: Robert Knoerl; Ellen M L Smith; Debra L Barton; David A Williams; Janean E Holden; John C Krauss; Beth LaVasseur Journal: J Pain Date: 2017-12-08 Impact factor: 5.820
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: Stephanie R Land; Jacek A Kopec; Reena S Cecchini; Patricia A Ganz; H Samuel Wieand; Linda H Colangelo; Kate Murphy; J Philip Kuebler; Thomas E Seay; Burton M Needles; James D Bearden; Lauren K Colman; Keith S Lanier; Eduardo R Pajon; David Cella; Roy E Smith; Michael J O'Connell; Joseph P Costantino; Norman Wolmark Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: Deirdre R Pachman; Rui Qin; Drew K Seisler; Ellen M L Smith; Andreas S Beutler; Lauren E Ta; Jacqueline M Lafky; Nina D Wagner-Johnston; Kathryn J Ruddy; Shaker Dakhil; Nathan P Staff; Axel Grothey; Charles L Loprinzi Journal: J Clin Oncol Date: 2015-08-17 Impact factor: 44.544
Authors: Fiona Yeo; Chiu Chin Ng; Kiley W J Loh; Alex Molassiotis; Hui Lin Cheng; Joseph S K Au; Kwun To Leung; Yu Chung Li; Kam-Hung Wong; Lorna Suen; Choi Wan Chan; Janelle Yorke; Carole Farrell; Aishwarya Bandla; Emily Ang; Violeta Lopez; Raghav Sundar; Alexandre Chan Journal: Support Care Cancer Date: 2019-04-10 Impact factor: 3.603
Authors: Cynthia S Bonhof; Daniëlle L van de Graaf; Dareczka K Wasowicz; Gerard Vreugdenhil; Floortje Mols Journal: Support Care Cancer Date: 2022-03-18 Impact factor: 3.359
Authors: Jeremy Chung Bo Chiang; David Goldstein; Azadeh Tavakoli; Terry Trinh; Jacob Klisser; Craig R Lewis; Michael Friedlander; Thomas J Naduvilath; Kimberley Au; Susanna B Park; Arun V Krishnan; Maria Markoulli Journal: Sci Rep Date: 2021-11-24 Impact factor: 4.379
Authors: Hsing-Wei Hung; Chien-Ying Liu; Hsiu-Fang Chen; Chun-Chu Chang; Shu-Ching Chen Journal: Int J Environ Res Public Health Date: 2021-05-26 Impact factor: 3.390
Authors: Hester R Trompetter; Cynthia S Bonhof; Lonneke V van de Poll-Franse; Gerard Vreugdenhil; Floortje Mols Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.603